Short answer: The iFIND S2/S4/S8 from RocGene (Kunpeng Gene) is a cartridge-based random-access platform that promises a fully automated sample-to-result workflow. But a brochure is not a procurement dossier. This guide separates the architecture’s appeal from the evidence gaps laboratory directors, distributors, and procurement teams must fill—analytical validation, clinical performance, and verified regulatory certificates—before shortlisting a fully automated molecular POCT system.
Editorial boundary: This article is for professional procurement and regulatory due diligence. It is not medical advice, does not validate any intended use, and does not establish market eligibility in any jurisdiction. Verify the current certificate, label, and instructions for use for the exact instrument model and assay catalogue number.
Laboratory managers evaluating a molecular POCT analyzer know that a closed cartridge, random-access capability and walk-away automation can shift testing closer to the patient. The iFIND platform—marketed as a 7-in-1 integrated system by Kunpeng Gene (Beijing) Technology Limited and distributed internationally under the RocGene brand—offers a modular architecture that stands out in a field of cartridge-based PCR analyzers. However, the English-language brochure supplied by the distributor contains no analytical or clinical performance data and only a surface-level regulatory label display. For more context on China-developed IVD systems, see our China & Global Biomed section. This guide equips procurement teams with a structured evidence checklist for the iFIND S2, S4, and S8 models.
What iFIND claims to automate
According to the manufacturer’s brochure (dated 2026-02-04), the iFIND system uses a closed microfluidic cartridge containing pre-loaded, lyophilized reagents. It integrates enrichment, ultrasonic extraction, membrane-adsorption purification, liquid handling, mixing, PCR amplification, and multi-channel fluorescence analysis into one workflow—described as a “7 in one” process. The company claims a sample-to-result time of 30–100 minutes, with dermatophyte testing stated as under 55 minutes.
The instrument uses a Peltier-based thermal cycler with a maximum heating rate of at least 11.5 °C/s and a cooling rate of at least 9.5 °C/s, achieving temperature accuracy and uniformity of ±0.1 °C. Fluorescence detection includes six or more channels (FAM, ROX, VIC, CY5, CY5.5, Atto 425), and the brochure states that the system can detect more than 10 targets in a single tube. Reagents are claimed to be stable at room temperature for two years, which could reduce cold-chain needs if the product label and transport conditions support that claim. The platform supports HL7 connectivity and operates on 100–240 V, 50/60 Hz. All these figures are manufacturer claims and have not been independently verified in the provided documentation.
iFIND S2, S4, S8: modular architecture at a glance
| Model | Independent Modules | Dimensions (L×W×H) | Weight | Key Implication |
|---|---|---|---|---|
| iFIND S2 | 2 | 260 × 320 × 365 mm | 15 kg | Smallest stated module count; intended site fit still requires workflow validation |
| iFIND S4 | 4 | 370 × 320 × 365 mm | 27 kg | Intermediate stated module count and footprint |
| iFIND S8 | 8 | 650 × 320 × 365 mm | 50 kg | Highest stated parallel capacity; requires more benchtop space |
The brochure describes each module as operating independently and the system as random access: different compatible cartridges may be loaded without waiting for a single fixed batch. If confirmed in workflow documentation, this design could improve turnaround-time flexibility. Real-world throughput still depends on assay duration, loading rules, staff availability, maintenance, and the mix of urgent and routine tests.
Where the brochure is strong
Several architectural features align with what many laboratories seek in a cartridge based PCR analyzer. The closed cartridge minimises contamination risk and reduces operator hands-on steps. Independent random-access modules allow simultaneous testing of different panels—a clear advantage over strictly batch-based instruments. The combination of ultrasonication extraction and membrane-adsorption purification is not trivial; it moves beyond simple binding-wash-elute columns. A stated room-temperature, two-year reagent shelf life, if validated in real-world shipping and storage conditions, would reduce logistics complexity. The detection of more than 10 targets in one cartridge, paired with six fluorescence channels, suggests multiplexing headroom that makes syndromic panels feasible.
The evidence gaps that matter
The brochure contains no clinical sensitivity, clinical specificity, limit of detection (LoD), invalid-rate data, interference, cross-reactivity, or carryover results for any assay. Without these, a procurement team cannot judge whether a test is fit for a specific clinical population or sample matrix. No peer-reviewed or manufacturer-sponsored evaluation of the cartridge in real-world workflows is provided. The sample-to-result times stated do not differentiate between processing steps and are unvalidated against an established reference method. The brochure also omits quality-control details: frequency of external positive and negative controls, internal control architecture, and pass/fail criteria for invalid runs.
Regulatory claims versus verifiable documents
| Brochure Claim | What It Could Mean | Document to Request | Critical Caveat |
|---|---|---|---|
| NMPA | China NMPA registration for certain models or assays | NMPA medical-device registration certificate with model numbers, intended use, and assay scope | A registration for one product does not automatically cover every assay in the brochure; verify the exact record in the NMPA database. |
| CE-IVDR (cover) / CE-IVD (menu) | May refer to marking under Regulation (EU) 2017/746 or to an older IVDD route still subject to applicable transition provisions | EU Declaration of Conformity, classification, authorised-representative details, applicable Notified Body certificate, and assay scope | The labels are not enough to establish the regulatory route. Classification, transition status, and whether Notified Body involvement is required must be checked for each product. |
| FDA | Could refer only to establishment registration and device listing rather than a cleared or approved device | 510(k), De Novo, PMA, or other authorisation number where applicable, plus current establishment and listing records | FDA registration and listing do not denote approval, clearance, or authorization. Search the relevant FDA premarket database as well as the registration and listing database. |
| UKCA | May indicate conformity with the route applicable in Great Britain | Declaration of Conformity, UK Responsible Person details, MHRA registration evidence, and Approved Body certificate where required | Current Great Britain rules include transition arrangements for eligible CE-marked devices. Verify the exact product against current MHRA guidance, not the cover label alone. |
Because the brochure displays “CE-IVDR” on its cover but “CE-IVD” on the test menu, the buyer must reconcile which regulatory pathway each assay followed. The labels do not establish whether a product follows the IVDR, an applicable IVDD transition route, or another status. Until the manufacturer provides the declaration, certificate where applicable, and an assay-by-assay mapping, no team should assume that all assays carry the same regulatory status.
Human IVD versus veterinary RUO: a critical boundary
The brochure’s menu separates human assays, labelled “CE-IVD,” from veterinary tests—African swine fever, feline and canine panels, toxoplasma, FIP-related targets, and feline anemia pathogens—marked “RUO” (Research Use Only). RUO products are not intended for clinical diagnostic procedures in animals and must not be substituted for validated veterinary diagnostic tests. Laboratories and distributors presented with an RUO panel for an animal health application must request a clear regulatory pathway, validation data, and intended-use statement specific to the target species and clinical setting. The presence of RUO assays does not diminish the human IVD menu, but mixing the two in a procurement discussion can create liability if the distinction is overlooked.
Procurement checklist: 12 points to verify before shortlisting
Intended use and accepted sample types. For each assay, request the exact intended use statement (e.g., screening, diagnosis, monitoring), specimen matrix (whole blood, swab, sputum), and population (adult, paediatric).
Current regulatory certificates and scope. Ask for NMPA registration, IVDR/EU certificate, UKCA certificate, and FDA documentation (clearance, listing only, or EUA). Confirm exact instrument models and assay catalogue numbers covered.
Analytical performance data. Obtain limit of detection (LoD) per target, linear dynamic range, precision (intra- and inter-assay CVs), cross-reactivity with near-neighbour organisms, and interference from common substances.
Clinical performance data. Request sensitivity, specificity, positive predictive value and negative predictive value against a validated comparator method, in a relevant population.
Invalid and indeterminate rate data. Specify the invalid-run frequency, reasons (e.g., internal control failure, clot, extraction failure), and retesting protocol.
Quality control and calibration requirements. Clarify whether the cartridge contains on-board controls, what external QC materials are required, calibration frequency, and whether each lot requires user calibration.
Contamination control evidence. Since cartridges are closed, request carryover data (sample-to-sample and assay-to-assay) and evidence that the design prevents amplicon aerosol release.
Throughput under realistic conditions. Model the daily throughput for your test mix with random-access loads, not just maximum theoretical runs. Consider staff shift patterns and downtime for maintenance.
LIS/HL7 connectivity documentation. Verify the version of HL7 supported, successful interface with your laboratory information system, and availability of middleware if needed.
Maintenance schedule and service response. Obtain the preventive maintenance plan, mean time to repair, availability of regional service engineers, and training requirements for key users.
Reagent supply, stability, and cost. Confirm lead times, shelf-life under actual shipping conditions, and whether single cartridges are sold or only packs. Calculate cost per test including all consumables and discard costs for expired reagents.
Total cost per reportable result. Build a model that amortises instrument price (or lease), service contract, reagent cost per cartridge, external QC, proficiency testing, staff time, and expected invalid-run replacement costs. The instrument sticker price is rarely the dominant cost driver.
Beyond the instrument price: modeling total cost per reportable result
Procurement teams focused on a molecular POCT analyzer often compare instrument quotes, but the true financial impact is in the total cost per patient result. For a cartridge-based PCR analyzer, factors such as cartridge cost per test, control and calibration costs, invalid-run replacement cartridges, service contracts, and the impact of random-access utilisation on throughput all shift the cost per reportable result. Without validated invalid-rate data, underutilised capacity, and reagent consumption patterns, any cost comparison is speculative. Buyers should request a detailed cost-of-test-model from the distributor that includes realistic run volumes, discard rates, and maintenance costs over the expected lifespan—and then challenge the assumptions with their own utilisation data.
The iFIND S2/S4/S8 platform is a technically interesting case study of modular, cartridge-based, random-access automation. Its closed cartridge design, ultrasound extraction, and multiplexing ambition align with the demands of a fully automated molecular POCT system. Yet the brochure alone cannot support a shortlisting decision. The absence of clinical performance data in the supplied material, the incomplete regulatory picture, and the RUO-only veterinary panels mean that international buyers must proceed with an evidence-first review. Until the manufacturer supplies current certificates, assay-specific validation, and a transparent cost-per-result model, the platform is not evidence-complete for a procurement decision based on this brochure alone.
Frequently asked questions
What defines a fully automated molecular POCT system?
A fully automated molecular POCT system integrates sample preparation, nucleic acid extraction, amplification, and detection in a single instrument with minimal operator intervention—ideally using a closed cartridge. It is designed to deliver a qualitative or quantitative result near the patient, often in under two hours, and may offer random-access capability.
Is the iFIND FDA cleared?
No FDA clearance, approval, or authorization number appears in the brochure. The “FDA” label on the cover could refer to establishment registration or device listing, but the supplied document does not define it. As the FDA states, registration and listing do not denote approval or clearance. A buyer should request the applicable premarket submission or authorization number and verify it directly in the relevant FDA database.
What does random access mean in molecular diagnostics?
Random access allows the user to load any compatible cartridge at any time on any available module. Each module runs independently, so one module can test a respiratory panel while another tests a mycobacteria assay, without waiting for a batch. This contrasts with batch-only platforms where all tests must start simultaneously.
How much does an iFIND cartridge-based PCR analyzer cost?
No public pricing is available in the supplied brochure. Costs vary by region, module count, reagent contracts, and service agreements. Teams must request a formal quotation and model the total cost per reportable result using their expected test volumes and cartridge pricing.
Sources
Manufacturer brochure
RocGene iFIND fully automated nucleic acid detection and analysis system brochure (English), creation date 2026-02-04, Kunpeng Gene (Beijing) Technology Limited. Supplied by distributor. All specifications, claims, and regulatory marks referenced in this article are taken from this document and attributed as manufacturer claims.